Abstracts tagged "outcomes and registries"

Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Johan Askling², Adrian Ciurea³, Eirik K Kristianslund⁴, Fatos Onen⁵, Dan Nordström⁶, Maria José Santos⁷, Catalin Codreanu⁸, Ziga Rotar⁹, Björn Gudbjornsson¹⁰, Daniela Di Giuseppe², Michael J. Nissen¹¹, Tore Kvien⁴, Merih Birlik⁵, Nina Trokovic⁶, Anabela Barcelos⁷, Ruxandra Ionescu⁸, Matija Tomšič⁹, Arni Jon Geirsson¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Tamara Rusman¹³, Juan J. Gomez-Reino¹⁴, Gareth T. Jones¹⁵, Florenzo Iannone¹⁶, Karel Pavelka¹², Irene van der Horst-Bruinsma¹⁷, Lise Hyldstrup¹, Niels Steen Krogh¹⁸, Merete Lund Hetland¹ and Mikkel Østergaard¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Zurich, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁸RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ⁹biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ¹⁰ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ¹¹SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Haarlem, Netherlands, ¹⁴BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁵BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁶GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁷ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁸Zitelab, EuroSpA Research Collaboration Network, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].